| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.corallab.com | |
| Market Cap | 92.91 Cr. | |
| Enterprise Value(EV) | 53.76 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 23.07 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 11.27 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 440.87 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 0.59 | Calculated using Price: 260.05 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.36 Cr. | 3,572,600 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors. The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”. The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification. Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments. Product range of the company includes:
Achievements/ recognition:
|
||
Company Profile
Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors.
The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”.
The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification.
Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments.
Product range of the company includes:
Achievements/ recognition:
| 1 Day |
|
+7.00% |
| 1 Week |
|
+5.46% |
| 1 Month |
|
-6.59% |
| 3 Month |
|
-8.41% |
| 6 Month |
|
-16.20% |
| 1 Year |
|
-36.16% |
| 2 Year |
|
+97.13% |
| 5 Year |
|
-75.65% |
| 10 Year |
|
+290.85% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 14.76 | 16.72 | 17.46 | 19.18 | 18.17 | 11.04 | 8.88 | 6.22 | 10.74 | |
| Return on Capital Employed (%) | 18.70 | 21.24 | 22.22 | 26.93 | 27.23 | 15.91 | 13.44 | 7.86 | 13.53 | |
| Return on Assets (%) | 11.25 | 13.25 | 14.40 | 15.32 | 14.77 | 9.17 | 7.40 | 5.09 | 8.69 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 44 | 51 | 59 | 70 | 109 | 116 | 114 | 116 | 137 | 157 | |
| Non Curr. Liab. | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 4 | 3 | 3 | |
| Curr. Liab. | 14 | 9 | 12 | 18 | 19 | 20 | 18 | 25 | 28 | 15 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 58 | 61 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 175 | |
| Non Curr. Assets | 24 | 23 | 22 | 25 | 58 | 68 | 52 | 48 | 57 | 72 | |
| Curr. Assets | 34 | 37 | 50 | 65 | 74 | 72 | 84 | 96 | 111 | 103 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 58 | 61 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 175 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 42 | 51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 83 | |
| Other Income | 1 | 1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 5 | |
| Total Income | 43 | 52 | 62 | 80 | 99 | 97 | 96 | 76 | 100 | 89 | |
| Total Expenditure | -34 | -41 | -47 | -61 | -72 | -77 | -79 | -65 | -80 | -74 | |
| PBIDT | 9 | 11 | 15 | 19 | 27 | 20 | 18 | 11 | 20 | 15 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Depreciation | -1 | -1 | -3 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | |
| Taxation | -2 | -2 | -3 | -5 | -8 | -6 | -5 | -2 | -4 | -4 | |
| Exceptional Items | 0 | 0 | 0 | ||||||||
| PAT | 6 | 8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 8 | |
| Adjusted EPS | 17 | 22 | 27 | 35 | 46 | 35 | 29 | 20 | 38 | 23 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 0 | 1 | 0 | 5 | 11 | 13 | -1 | -4 | 1 | |
| Cash Fr. Inv. | 0 | 0 | 1 | 0 | -3 | -10 | -13 | 3 | -2 | 0 | |
| Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -1 | 4 | 0 | |
| Net Change | 3 | 1 | 2 | 0 | 2 | 1 | -2 | 1 | -2 | 1 | |
| Cash & Cash Eqvt | 4 | 5 | 7 | 7 | 9 | 4 | 2 | 3 | 1 | 2 |
|
Fri, 20 May 2022
Board Meeting Intimation for Notice Under Regulation 29(1) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 CORAL LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve 1.Standalone Audited Financial Results for the Quarter and Financial Year Ended March 31 2022.2. Appointment of Secretarial Auditor.3.Any other business with the permission of chairman. |
|||||||||||||||||||||
|
Tue, 19 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Ruchi Anjaria Designation: Company Secretary and Compliance Officer EmailId: cs@corallab.com Name of the Chief Financial Officer: Sushma Kadkade Designation: Director and CFO EmailId: accounts@corallab.com Date: 19/04/2022 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Fri, 15 Apr 2022
Compliance Certificate From PCS As Per Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As per the requirement of the Regulation 40(9) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith Original Certificate from practicing Company Secretaries M/s SARK & Associates in compliance with requirement under Regulation 40(10) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended March 31 2022. |
| Fri, 20 May 2022 |
High Delivery Percentage
|
Opening at Low
|
Closing Above Previous High
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors